Media Details

  • Home
  • Media
  • Details
  2020-12-07 13:40:24


KUALA LUMPUR, 07 December 2020 – HWGB Biotech Sdn Bhd (“HWGB Biotech”), wholly owned subsidiary of Ho Wah Genting Berhad’s (“HWGB” or the “Company”) (Bursa Stock Code:9601), had today submitted a letter to the Ministry of Science, Technology and Innovation Malaysia (“MOSTI”) to explore potential collaboration on its research study and to explore potential collaboration on the distribution of the E-Mo Covid-19 Vaccine developed by E-Mo Biology Inc. (“EBI”) upon approval by US Food And Drug Administration being obtained.
This potential collaboration with MOSTI will support HWGB Biotech’s participation in research study on the Covid-19 vaccine and it is also a positive step for HWGB Biotech efforts to plan for the distribution of EBI’s E-Mo Covid-19 Vaccine in Malaysia. It is HWGB Biotech’s aim to provide a safe, affordable and easily accessible vaccine to ensure the well-being of all Malaysians and to significantly reduce the number of COVID-19 cases in the country.
HWGB Biotech Sdn Bhd’s General Manager, Medical & Pharmaceutical Research, Dr. Yaman Walid Kassab, said: “When successful, it can help our economy recover quicker and hopefully open borders to other countries or cities for leisure and business purposes, following in the footsteps of Singapore and Hong Kong. In light of the current COVID-19 situation in Malaysia, it is imperative for us to work fast to provide a safe, affordable and easily accessible vaccine for the masses to ensure immunity to COVID-19. It is my sincerest hope that HWGB Biotech receives the necessary support from MOSTI on the distribution of the COVID-19 vaccine produced by EBI, to improve the health for all.”



Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in health supplement, biotechnology and health technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wires and cables; and travel agent and tour related services.

HWGB Biotech Sdn Bhd, was incorporated on 18 June 2012 under the Companies Act, 1965 under the former name of HWG Consortium Sdn Bhd and changed to its current name on 22 May 2020. HWGB Biotech is principally involved in the ddistribution of all kinds of biotechnology products, bioinformatics diagnostic tools, all medical engineering equipment along with software developments and tools as well as to patent all original products and by-products, technologies and software developed or sourced by the company.

Please refer to the US Food and Drug Administration website for more information on EBI’s Phase IV clinical study :

For more information on about HWGB Biotech, follow us on,, Facebook, LinkedIn and Telegram to view the latest updates about our company ventures in the healthcare industry.
Dr.Yaman Walid Kassab is an assistant Professor of Clinical Pharmacy. He obtained his PhD in Clinical Pharmacy at University Science Malaysia (USM) in 2013. He possesses 7 years of experience in the academia, specifically in the pharmacotherapy field. He is actively involved in medical research and publication and has published more than 40SCOPUS/ISI indexed research papers and has supervised more than 50 research projects and 20 postgraduate research students. He is also serving as an editorial Board member of several reputed international journals like “Frontiers in Pharmacology”, “Archives of Pharmacy Practice (APP)” , “Journal of Medical and Pharmaceutical Innovation (JMPI)” , ”Annals of Cardiology and Cardiovascular Diseases” , “Updates in Public Health and Preventive Medicine” He has been a member of many international professional bodies such as International Association of Therapeutic Drug Monitoring & Clinical Toxicology in CANADA, Syndicate of Syrian Pharmacists, Malaysian Association of Education in Medicine & Health Sciences, Malaysian Pharmaceutical Society.
E-Mo Biology Inc (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Dr. Xie QiYi, who serves as its Managing Director of EBI. He has over 30 years of experience in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.